clindamycin phosphate · Pfizer · NDA 050537, 050680, 050767
Cleocin
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 218300, Rising · 050537-002Approved 23 Mar 2026Detected 25 Oct 2026Historical import
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 050537 · 002 · RLD · discontinued | swab, topical | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 050680 · 001 · discontinued | cream, vaginal | EQ 2% BASE | open |
| 050680 · 002 · RLD | cream, vaginal | EQ 2% BASE | open |
| 050767 · 001 · RLD | suppository, vaginal | 100MG | open |